Okyo Pharma Ltd Stock Piotroski F Score
| OKYO Stock | USD 1.04 0.01 0.95% |
OKYO | Piotroski F Score |
At this time, it appears that OKYO Pharma's Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
2.0
Piotroski F Score - Frail
| Current Return On Assets | Negative |
| Change in Return on Assets | Decreased |
| Cash Flow Return on Assets | Negative |
| Current Quality of Earnings (accrual) | Decreasing |
| Asset Turnover Growth | No Change |
| Current Ratio Change | Decrease |
| Long Term Debt Over Assets Change | N/A |
| Change In Outstending Shares | Decrease |
| Change in Gross Margin | No Change |
OKYO Pharma Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to OKYO Pharma is to make sure OKYO is not a subject of accounting manipulations and runs a healthy internal audit department. So, if OKYO Pharma's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if OKYO Pharma's financial numbers are properly reported.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Current Liabilities | 7.8 M | 7.4 M |
|
| |||||
| Total Assets | 1.5 M | 1.5 M |
|
| |||||
| Total Current Assets | 1.5 M | 1.5 M |
|
|
OKYO Pharma F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between OKYO Pharma's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards OKYO Pharma in a much-optimized way.
| -0.47 | 0.23 | -0.33 | 0.38 | 0.23 | -0.33 | ||
| -0.47 | 0.44 | 0.02 | -0.8 | -0.86 | -0.26 | ||
| 0.23 | 0.44 | -0.39 | -0.51 | -0.39 | -0.89 | ||
| -0.33 | 0.02 | -0.39 | -0.1 | -0.03 | 0.12 | ||
| 0.38 | -0.8 | -0.51 | -0.1 | 0.8 | 0.31 | ||
| 0.23 | -0.86 | -0.39 | -0.03 | 0.8 | 0.28 | ||
| -0.33 | -0.26 | -0.89 | 0.12 | 0.31 | 0.28 |
Click cells to compare fundamentals
About OKYO Pharma Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.Book Value Per Share |
|
OKYO Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of OKYO Pharma from analyzing OKYO Pharma's financial statements. These drivers represent accounts that assess OKYO Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of OKYO Pharma's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.7B | 1.8B | 3.5B | 37.4M | 43.1M | 41.0M | |
| Enterprise Value | 1.7B | 1.8B | 3.5B | 35.6M | 42.3M | 40.2M |
About OKYO Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze OKYO Pharma Ltd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of OKYO Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of OKYO Pharma Ltd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with OKYO Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if OKYO Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OKYO Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against OKYO Stock
The ability to find closely correlated positions to OKYO Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace OKYO Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back OKYO Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling OKYO Pharma Ltd to buy it.
The correlation of OKYO Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as OKYO Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if OKYO Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for OKYO Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out OKYO Pharma Altman Z Score, OKYO Pharma Correlation, OKYO Pharma Valuation, as well as analyze OKYO Pharma Alpha and Beta and OKYO Pharma Hype Analysis. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OKYO Pharma. If investors know OKYO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OKYO Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.57) | Return On Assets (2.92) | Return On Equity (29.69) |
The market value of OKYO Pharma is measured differently than its book value, which is the value of OKYO that is recorded on the company's balance sheet. Investors also form their own opinion of OKYO Pharma's value that differs from its market value or its book value, called intrinsic value, which is OKYO Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OKYO Pharma's market value can be influenced by many factors that don't directly affect OKYO Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OKYO Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if OKYO Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OKYO Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.